Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group

学, 森本; 和司, 沼田; 正晃, 近藤; 央, 日高; 樹一, 高田; 明隆, 渋谷; 薫, 宮川; 伸一, 大川; 千晃, 奥瀬; 克明, 田中

doi:10.2957/kanzo.51.411

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OUR PREVIOUS REPORT 8 indicated that median treatment duration and incidence of ADRs were not statistically different with increasing age; however, age ≥75 years was an important prognostic factor for lower OS. To reevaluate the relationship between patient age and drug safety, we conducted a secondary analysis using the same cohort and found that sorafenib has modest efficacy and tolerable ADRs in younger (<75 years) Japanese patients with advanced HCC; however, more than 40% of the elderly patients (≥75 years) who received the standard dosage (400 mg twice daily) discontinued the treatment because of ADRs.…”

Section: Discussionmentioning

confidence: 99%

“…In global trials including non‐Japanese populations, sorafenib was generally well tolerated; 4–7 however, their average age at presentation was relatively young (age range, 51–69 years). On the other hand, in our previous study of sorafenib treatment in Japanese patients with HCC, 8 the average age at presentation (70.3 years) was much older than in the previous trials, 4–7 and increasing age (≥75 years) was an important prognostic factor for lower overall survival (OS). At present, the efficacy and tolerability of this drug in elderly patients with advanced HCC is not clear; therefore, we conducted a secondary retrospective analysis of this multicenter trial 8 to evaluate the efficacy and tolerability of sorafenib with increasing age.…”

Section: Introductionmentioning

confidence: 87%

See 1 more Smart Citation

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Morimoto

Numata

Kondo

et al. 2011

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 87%

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Morimoto

Numata

Kondo

et al. 2011

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this study, sorafenib significantly prolonged OS, with an increase in median OS from 4.2 to 6.5 months [85]. However, reduced duration of sorafenib treatment associated with drugrelated adverse events decreased its efficacy compared with previous studies [2,85], although the study population was based on a local Japan area [86]. Currently, the indication of sorafenib in Child-Pugh B patients is open to dispute.…”

Section: Sorafenibmentioning

confidence: 88%

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Sato¹,

Mori

2011

CMC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide. Unresectable or metastatic HCC has a poor prognosis, and systemic cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. However, there has been increasing interest in developing novel molecularly targeted agents in HCC due to the accumulation of knowledge of cell signaling and molecular carcinogenesis. Furthermore, some of these agents have proven to be efficacious in other traditionally challenging carcinomas, such as renal cell carcinoma. Recently, a phase III, randomized, placebo-controlled trial demonstrated that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor and Ras kinase, improves overall survival (OS) in patients with advanced HCC. This seminal study described the first agent to improve OS in HCC and began a new era of molecule-targeted cancer therapies. Currently, many novel molecularly targeted agents are under evaluation in clinical trials. In this review, we comprehensively summarize the molecular pathogenesis, targets, and signal transduction pathways involved in HCC. We also detail the current status of molecularly targeted agents that are under clinical development in advanced HCC, including the mechanisms of action of these agents.

show abstract

Current Status of Hepatocellular Carcinoma Treatment in Japan

et al. 2012

View full text Add to dashboard Cite

The efficacy of sorafenib in hepatocellular carcinoma (HCC) has been demonstrated in two pivotal clinical trials: the European SHARP trial and a second trial that recruited patients in the Asia-Pacific region. Sorafenib was approved for the treatment of advanced HCC in Japan based on the results of these studies. This article presents experiences with sorafenib in patients with HCC at three institutions in Japan, representing the viewpoints of a liver surgeon and a hepatologist at university hospitals, and a hepatologist at a community hospital. The three physicians discuss representative cases and current clinical practice at their institutions, and their recommendations for the use of sorafenib in the wider clinical setting. Overall, the experiences at these institutions show that sorafenib is most effective when administered for a long time, and the management of adverse events (AEs) [including dose-reduction and modification] is critical to achieving high levels of adherence to treatment. A team-focussed treatment strategy that includes patient counselling and follow-up can contribute to managing AEs to ensure successful continuation of sorafenib therapy. In addition, a proposed definition of unresponsiveness to transarterial chemoembolization and the implications of treatment lag on the outcomes of sorafenib therapy, as well as measures for the prevention and treatment of hand-foot skin reaction are discussed.

show abstract

Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group

Cited by 6 publications

References 16 publications

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Current Status of Hepatocellular Carcinoma Treatment in Japan

Contact Info

Product

Resources

About